Novartis

Novartis sickle cell drug Adakveo put on path to EU approval
Clinical News

Novartis sickle cell drug Adakveo put on path to EU approval

Novartis announced last Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization of Adakveo® (crizanlizumab)…
Back to top button
Close
Close